RE:RE:NEWS/INFOleonenoel wrote:
where did you get this? is it a separate news release?
Toronto, Ontario – TheNewswire – May 4, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is excited to announce that it is receiving advisory services and research and development funding of up to $120,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to further enhance cardiac measurement capabilities of the VMS+. This funding is a continuation of a previously successful NRC IRAP-funded project that resulted in the development of VMS+3.0.
“We value this support from NRC IRAP as we strive to bring innovative products to market and further our mission to improve healthcare outcomes,” said George Adams, Executive Chairman of Ventripoint Diagnostics Ltd.
The next generation of the VMS+ will incorporate advanced cardiac measurement features to add further clinical value to the VMS+ product thereby improving healthcare outcomes. The primary objective of this new proposed product is to provide a complete echo cardiac analysis package with conventional 2D measurements as well as the 3D measurements currently uniquely provided by the VMS+ using 2D ultrasound. This will provide more quantitative data to clinicians and a visual aid to outline the interrelationships of the heart. These product advances will play a role in helping in the prevention and diagnosis of cardiac disease globally. This is especially relevant today with the need for thorough assessment of cardiac conditions due to COVID-19.